Martine Piccart

Research interests

Publications

• Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2105215

• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2028485

• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.01010

• Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

  Annals of Oncology · 2019 · 10.1093/annonc/mdz235

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · 10.1093/annonc/mdx308

• Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1703643

• 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(16)32616-2

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30777-5

• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1602253

• 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

  Annals of Oncology · 2016 · 10.1093/annonc/mdw544

• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu112

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2011.41.0902

• CD4+ follicular helper T cell infiltration predicts breast cancer survival

  Journal of Clinical Investigation · 2013 · 10.1172/jci67428

• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(11)61847-3

• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1109653

• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2765

• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

  The Lancet · 2007 · 10.1016/s0140-6736(07)60028-2

• Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj052

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

• Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

  JNCI Journal of the National Cancer Institute · 2005 · 10.1093/jnci/dji250

• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa052306

• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

  New England Journal of Medicine · 2003 · 10.1056/nejmoa032312

Current projects

No projects listed.